Lexicon Pharmaceuticals (NASDAQ:LXRX) reported fourth-quarter financial results on Thursday that exceeded Wall Street expectations, driven by reduced operating expenses and licensing revenue.
Regenxbio (NASDAQ:RGNX) shares faced pressure Thursday after the biotechnology company reported fourth-quarter financial results that trailed Wall Street expectations on both the top and bottom lines.
MediWound (NASDAQ:MDWD), a biopharmaceutical developer focused on enzymatic therapeutics for tissue repair, reported fourth-quarter losses that were narrower than analysts had anticipated.
Bioventus (NASDAQ:BVS) reported a return to profitability for the full year 2025, supported by a strong fourth-quarter performance that saw organic revenue accelerate across its core healing therapies.
HUTCHMED (NASDAQ:HCM) reported a net income of $456.9 million for the full year 2025, a nearly 12-fold increase from the prior year, primarily driven by a one-time divestment gain and the continued global expansion of its oncology portfolio.
National Vision Holdings (NASDAQ:EYE) unveiled fourth-quarter and full-year 2025 results on Wednesday, marking its 12th consecutive quarter of positive comparable store sales growth as the optical retailer successfully navigates its post-Walmart transition.
TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-engineered T cell therapies for the treatment of cancer, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update focused on progress across its allogeneic TCR-T platform.
Ocugen (NASDAQ:OCGN), a Malvern, Pennsylvania-based clinical-stage biotechnology company developing modifier gene therapies for ophthalmic and other diseases, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update highlighting progress across its three lead modifier gene therapy programs.
Cellectar Biosciences (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company specializing in radioconjugates, reported a significantly reduced net loss for 2025 as it transitioned its lead program, iopofosine I-131, into the final regulatory stages.
EyePoint Pharmaceuticals (NASDAQ:EYPT) entered a critical catalyst year on Wednesday, reporting full-year 2025 results and a clinical roadmap that places its lead candidate, DURAVYU, on track for its first pivotal Phase 3 readout in just months.
Stevanato Group (NYSE:STVN) reported a 19% increase in annual earnings on Wednesday, as the Italian drug containment specialist successfully leveraged a record mix of high-value products to offset persistent headwinds in its engineering segment.
HUTCHMED (NASDAQ:HCM) announced Wednesday the initiation of a Phase I/IIa clinical trial for HMPL-A580, marking the first human testing of its second antibody-targeted therapy conjugate (ATTC) for the treatment of solid tumors.
